Pharmaceuticals, Biotechnology and Life Sciences
Telix Pharmaceuticals and German Cancer Research Center (Deutsches Krebsforschungszentrum or DKFZ) have agreed to work together in the field of image-guided surgery for prostate cancer.
Johnson & Johnson’s Janssen has welcomed the news from Health Canada as it got approval to use Zytiga combined with prednisone…
The U.S. Food and Drug Administration has approved Janssen Pharmaceutical ‘sErleada (apalutamide) for the treatment of patients with prostate cancer that has…
MDxHealth has announced that results from a study published in The Prostate further validated ConfirmMDx for Prostate Cancer and showed that the test can provide treating urologists with deeper insights into a patient`s risk for aggressive prostate cancer.
Scientists have developed a new three-in-one blood test that has the potential to turn AstraZeneca’s drug Lynparza into a precision medicine for prostate cancer.
Roche has announced the global launch of the anti-p504s (SP116) Rabbit Monoclonal Primary Antibody2 for prostate cancer diagnosis.
Jansen revealed results from its real-world study of its cancer drug Zytiga in combination with Prednisone, to treat men with prostate cancer.
US Government Services Administration (GSA) has awarded MDxHealth to supply Department of Veterans Affairs (VA) with ConfirmMDx for Prostate Cancer.
Horizon Blue Cross Blue Shield (Horizon BCBS) of New Jersey has issued a positive medical policy for the MDxHealth’s ConfirmMDx for Prostate Cancer test.
European Patent Office has granted ValiRx’s patent covering its major therapeutic compound VAL201, including prostate cancer, the pharmaceutical company said on…